Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study

The Lancet Infectious Diseases

Volumn 17, Issue 2, 2017, Pages 215-222

  Deterding, Katja ^a,b   Spinner, Christoph D ^c   Schott, Eckart ^d   Welzel, Tania M ^e   Gerken, Guido ^f   Klinker, Hartwig ^g   Spengler, Ulrich ^h   Wiegand, Johannes ⁱ   zur Wiesch, Julian Schulze ^j   Pathil, Anita ^k   Cornberg, Markus ^a,b,l   Umgelter, Andreas ^c   Zöllner, Caroline ^d   Zeuzem, Stefan ^e   Papkalla, Armin ^m   Weber, Kristina ^a   Hardtke, Svenja ^b,l   von der Leyen, Heiko ^m   Koch, Armin ^a   von Witzendorff, Dorothee ^b   Manns, Michael P ^a,b,l   Wedemeyer, Heiner ^a,b,l   more..

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b GERMAN RESEARCH FOUNDATION   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^f UNIVERSITY HOSPITAL ESSEN   (Germany)

^g UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^h UNIVERSITY HOSPITAL BONN   (Germany)

ⁱ UNIVERSITY OF LEIPZIG   (Germany)

^j UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^k UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^l HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^m Hannover Clinical Trial Center   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

LEDIPASVIR PLUS SOFOSBUVIR; VIRUS RNA; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; LEDIPASVIR; SOFOSBUVIR;

ABDOMINAL PAIN; ACUTE HEPATITIS C; ADULT; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL OUTCOME; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EYE DISEASE; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HEADACHE; HEPATITIS C VIRUS GENOTYPE 1; HIGH RISK POPULATION; HUMAN; MALE; MOUTH DISEASE; MULTICENTER STUDY; NONHUMAN; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SKIN MANIFESTATION; SLEEP DISORDER; SPLEEN DISEASE; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; BLOOD; CLASSIFICATION; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG EFFECT; GENETICS; GERMANY; HEPACIVIRUS; HEPATITIS C; MIDDLE AGED;

ANTIVIRAL AGENTS; BENZIMIDAZOLES; DRUG THERAPY, COMBINATION; FEMALE; FLUORENES; GERMANY; HEPACIVIRUS; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RNA, VIRAL; SOFOSBUVIR;

EID: 85005951075     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(16)30408-X     Document Type: Article

References (30)

1. 1 Grebely, J, Prins, M, Hellard, M, et al. Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis 12 (2012), 408–414.
2. 2 Deterding, K, Wiegand, J, Gruner, N, et al. The German Hep-Net acute hepatitis C cohort: impact of viral and host factors on the initial presentation of acute hepatitis C virus infection. Z Gastroenterol 47 (2009), 531–540.
3. 3 Deterding, K, Gruner, N, Buggisch, P, et al. Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. Lancet Infect Dis 13 (2013), 497–506.
4. 4 Jacka, B, Applegate, T, Poon, AF, et al. Transmission of hepatitis C virus infection among younger and older people who inject drugs in Vancouver, Canada. J Hepatol 64 (2016), 1247–1255.
5. 5 Martinez-Bauer, E, Forns, X, Armelles, M, et al. Hospital admission is a relevant source of hepatitis C virus acquisition in Spain. J Hepatol 48 (2008), 20–27.
6. 6 Santantonio, T, Fasano, M, Sagnelli, E, et al. Acute hepatitis C: a 24-week course of pegylated interferon alpha-2b versus a 12-week course of pegylated interferon alpha-2b alone or with ribavirin. Hepatology 59 (2014), 2101–2109.
7. 7 Hullegie, SJ, Claassen, MA, van den Berk, GE, et al. Boceprevir, peginterferon and ribavirin for acute hepatitis C in HIV infected patients. J Hepatol 64 (2016), 807–812.
8. 8 Doyle, JS, Deterding, K, Grebely, J, et al. Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort. J Viral Hepat 22 (2015), 1020–1032.
9. 9 Jaeckel, E, Cornberg, M, Wedemeyer, H, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 345 (2001), 1452–1457.
10. 10 Wiegand, J, Buggisch, P, Boecher, W, et al. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology 43 (2006), 250–256.
11. 11 Pawlotsky, JM, Feld, JJ, Zeuzem, S, Hoofnagle, JH, From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol 62:suppl (2015), S87–S99.
12. 12 European Association for Study of Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 63 (2015), 199–236.
13. 13 Wedemeyer, H, Towards interferon-free treatment for all HCV genotypes. Lancet 385 (2015), 2443–2445.
14. 14 Rockstroh JK, Bhagani S, Hyland RH, et al. Ledipasvir/sofosbuvir for 6 weeks in HIV-infected patients with acute HCV infection. Conference on Retroviruses and Opportunistic Infections (CROI) 2016; Boston, MA, USA; Feb 22–25, 2016. Abstract 154LB.
15. 15 Fierer, DS, Zachary, B, Dieterich, D, et al. Sofosbuvir in the treatment of acute HCV infection in HIV-infected men. Hepatology, 62(suppl 1), 2015 abstract 1090.
16. 16 Basu, P, Niraj, JS, Aloysius, M, Brown, R, Sofosbuvir and ledipasvir versus sofosbuvir and simeprevir combination therapy in the management of acute hepatitis C: a randomized open label prospective clinical pilot study. SLAM C study. Interim data. Hepatology, 62(suppl 1), 2015 abstract 1074.
17. 17 Naggie, S, Kristen, MM, Hughes, M, et al. Sofosbuvir plus ribavirin without interferon for treatment of acute hepatitis C virus infection in HIV-1 infected individuals (SWIFT-C). Hepatology, 62(suppl 1), 2015 abstract 1094.
18. 18 Fierer, DS, Douglas, D, Mullen, MP, et al. Telaprevir in the treatment of acute HCV infection in HIV-infected men: final results. Hepatology, 62(suppl 1), 2015 abstract 1112.
19. 19 Lawitz, E, Poordad, FF, Pang, PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 383 (2014), 515–523.
20. 20 Maasoumy, B, Vermehren, J, Welker, MW, et al. Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens. J Hepatol 65 (2016), 473–482.
21. 21 Hengst, J, Strunz, B, Deterding, K, et al. Nonreversible MAIT cell-dysfunction in chronic hepatitis C virus infection despite successful interferon-free therapy. Eur J Immunol 46 (2016), 2204–2210.
22. 22 Martin, B, Hennecke, N, Lohmann, V, et al. Restoration of HCV-specific CD8+ T cell function by interferon-free therapy. J Hepatol 61 (2014), 538–543.
23. 23 Rehermann, B, Bertoletti, A, Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections. Hepatology 61 (2015), 712–721.
24. 24 Owusu Sekyere, S, Suneetha, PV, Hardtke, S, et al. Type I interferon elevates co-regulatory receptor expression on CMV- and EBV-specific CD8 T cells in chronic hepatitis C. Front Immunol, 6, 2015, 270.
25. 25 Serti, E, Park, H, Keane, M, et al. Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFNα. Gut, 2016, 10.1136/gutjnl-2015-310033 published online Jan 4.
26. 26 Spaan, M, van Oord, G, Kreefft, K, et al. Immunological analysis during interferon-free therapy for chronic hepatitis C virus infection reveals modulation of the natural killer cell compartment. J Infect Dis 213 (2016), 216–223.
27. 27 Flynn, JK, Dore, GJ, Matthews, G, et al. Impaired hepatitis C virus (HCV)-specific interferon-æ responses in individuals with HIV who acquire HCV infection: correlation with CD4(+) T-cell counts. J Infect Dis 206 (2012), 1568–1576.
28. 28 Duffy, D, Mamdouh, R, Laird, M, et al. The ABCs of viral hepatitis that define biomarker signatures of acute viral hepatitis. Hepatology 59 (2014), 1273–1282.
29. 29 Rich, ZC, Chu, C, Mao, J, et al. Facilitators of HCV treatment adherence among people who inject drugs: a systematic qualitative review and implications for sclae up of direct acting antivirals. BMC Public Health, 16, 2016, 994.
30. 30 Wedemeyer, H, Duberg, AS, Buti, M, et al. Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat 21:suppl 1 (2014), 60–89.